The fecal mycobiome in non-alcoholic fatty liver disease

[1]  Jeong Hwan Park,et al.  Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD , 2020, Nature Communications.

[2]  B. Schnabl,et al.  Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future. , 2020, Cell host & microbe.

[3]  F. Lammert,et al.  Prediction of advanced fibrosis in non-alcoholic fatty liver disease using gut microbiota-based approaches compared with simple non-invasive tools , 2020, Scientific Reports.

[4]  R. Bataller,et al.  Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis , 2020, Hepatology.

[5]  R. Bloomer,et al.  Time of Feeding Alters Obesity-Associated Parameters and Gut Bacterial Communities, but Not Fungal Populations, in C57BL/6 Male Mice , 2020, Current developments in nutrition.

[6]  R. Loomba,et al.  The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH , 2019, Hepatology.

[7]  James T. Morton,et al.  Establishing microbial composition measurement standards with reference frames , 2019, Nature Communications.

[8]  J. Heitman,et al.  Gastrointestinal microbiota alteration induced by Mucor circinelloides in a murine model , 2019, Journal of Microbiology.

[9]  H. Sokol,et al.  Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis , 2019, Gut.

[10]  E. Bugianesi,et al.  NASH in Lean Individuals , 2019, Seminars in Liver Disease.

[11]  A. Diehl,et al.  Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis , 2017, The New England journal of medicine.

[12]  Gabriel A. Al-Ghalith,et al.  High-Fat Diet Changes Fungal Microbiomes and Interkingdom Relationships in the Murine Gut , 2017, mSphere.

[13]  D. Underhill,et al.  Commensal Fungi in Health and Disease. , 2017, Cell host & microbe.

[14]  Y. Koyama,et al.  Intestinal fungi contribute to development of alcoholic liver disease , 2017, The Journal of clinical investigation.

[15]  P. Caraceni,et al.  Epidemiology and outcomes of bloodstream infection in patients with cirrhosis. , 2014, Journal of hepatology.

[16]  E. Kim,et al.  Spontaneous fungal peritonitis: a severe complication in patients with advanced liver cirrhosis , 2014, European Journal of Clinical Microbiology & Infectious Diseases.

[17]  Ó. Zaragoza,et al.  It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug , 2012, Front. Microbio..

[18]  D. Kontoyiannis,et al.  Epidemiology and clinical manifestations of mucormycosis. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  G. Veres,et al.  Presence of Anti-Microbial Antibodies in Liver Cirrhosis – A Tell-Tale Sign of Compromised Immunity? , 2010, PloS one.

[20]  Vincent Wai-Sun Wong,et al.  Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years , 2010, Gut.

[21]  A. Levin,et al.  Candida colonisation as a source for candidaemia. , 2009, The Journal of hospital infection.

[22]  N. Kim,et al.  Spontaneous cryptococcal peritonitis in patients with liver cirrhosis. , 2004, The American journal of medicine.